135 related articles for article (PubMed ID: 7680271)
1. The value of prostate-specific antigen levels in pelvic lymph nodes for diagnosing metastatic spread of prostate cancer.
Shoskes DA; Trachtenberg J
Can J Surg; 1993 Feb; 36(1):33-6. PubMed ID: 7680271
[TBL] [Abstract][Full Text] [Related]
2. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
3. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Stone NN; Stock RG
Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102
[TBL] [Abstract][Full Text] [Related]
5. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
[TBL] [Abstract][Full Text] [Related]
6. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
7. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.
Edelstein RA; Zietman AL; de las Morenas A; Krane RJ; Babayan RK; Dallow KC; Traish A; Moreland RB
Urology; 1996 Mar; 47(3):370-5. PubMed ID: 8633404
[TBL] [Abstract][Full Text] [Related]
8. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
9. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
[TBL] [Abstract][Full Text] [Related]
11. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
[TBL] [Abstract][Full Text] [Related]
12. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
14. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Heidenreich A; Varga Z; Von Knobloch R
J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
[TBL] [Abstract][Full Text] [Related]
15. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
16. The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?
Gingrich JR; Paulson DF
Surg Oncol Clin N Am; 1995 Apr; 4(2):335-44. PubMed ID: 7540939
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate].
Saad F; Bertrand P; Paquin JM; Péloquin F
Ann Chir; 1995; 49(8):680-4. PubMed ID: 8561420
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
Fujita K; Nakayama M; Nakai Y; Takayama H; Nishimura K; Ujike T; Nishimura K; Aozasa K; Okuyama A; Nonomura N
Cancer Sci; 2009 Jun; 100(6):1047-50. PubMed ID: 19385972
[TBL] [Abstract][Full Text] [Related]
19. Predicting pelvic lymph node involvement in patients with localized prostate cancer.
Ekman P
Eur Urol; 1997; 32 Suppl 3():60-4. PubMed ID: 9267787
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
